Virax Biolabs Group (VRAX) Short Interest Ratio & Short Volume

Short interest is the volume of Virax Biolabs Group shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 446,500 shares of VRAX short. 11.02% of Virax Biolabs Group's shares are currently sold short. Learn More on Virax Biolabs Group's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.02% of Virax Biolabs Group's floating shares are currently sold short.

Virax Biolabs Group saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 446,500 shares, an increase of 92.6% from the previous total of 231,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Virax Biolabs Group currently has issued a total of 3,230,000 shares. Some of Virax Biolabs Group's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Virax Biolabs Group currently has a public float of 4,050,000 shares.

11.02% of Virax Biolabs Group's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Virax Biolabs Group: BioXcel Therapeutics, Inc. (0.81%), Lakeshore Biopharma Co., Ltd. (0.42%), Calidi Biotherapeutics, Inc. (6.56%), Lisata Therapeutics, Inc. (0.25%), Exicure, Inc. (4.71%), Cadrenal Therapeutics, Inc. (9.06%), Forte Biosciences, Inc. (0.08%), Chemomab Therapeutics Ltd. (1.29%), Tempest Therapeutics, Inc. (11.82%), Pulmatrix, Inc. (0.19%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling VRAX is an investing strategy that aims to generate trading profit from Virax Biolabs Group as its price is falling. VRAX shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Virax Biolabs Group occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VRAX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VRAX, twice per month. The most recent reporting period available is October, 31 2024.